Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response

NCT01850004 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
84
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Bristol-Myers Squibb

Collaborators